217 related articles for article (PubMed ID: 33739967)
1. New treatments for patients with progressive metastatic urothelial carcinoma.
Rosenberg JE
Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
[No Abstract] [Full Text] [Related]
2. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
3. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
4. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
Dhariwal R; Pindoria N; Dasgupta P; Khan MS
BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
[No Abstract] [Full Text] [Related]
5. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
Balar AV
Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
[No Abstract] [Full Text] [Related]
7. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
10. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E; Assi T; Kattan J
Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
[No Abstract] [Full Text] [Related]
11. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
Le Brun IC; Benderra MA
Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742
[No Abstract] [Full Text] [Related]
12. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
14. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
15. Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer.
Zillioux J; DiLizia M; Schaheen B; Rustin R; Krupski TL
Can J Urol; 2018 Oct; 25(5):9525-9526. PubMed ID: 30281011
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
18. Urothelial cancers: using biology to improve outcomes.
Pezaro C; Liew MS; Davis ID
Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
20. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]